

INFORMATION DISCLOSURE STATEMENT


Applicant : Gadde, Kishore M.
App. No : 10/830,071
Filed : April 23, 2004
For : METHOD FOR TREATING OBESITY
Examiner : Unassigned
Art Unit : Unassigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 26, 2005

(Date)


Sam K. Tahmassebi, Reg. No. 45,151

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing twenty five (25) references that are of record in U.S. patent application No. 10/440,404, filed May 19, 2003, which is the parent of this continuation application, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan. 26, 2005

By: 

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/830,071
 Filing Date April 23, 2004
 First Named Inventor Gadde, Kishore M.
 Art Unit Unassigned
 Examiner Unassigned
 Attorney Docket No. OREX.009C1

(Multiple sheets used when necessary)

SHEET 1 OF 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,172,896	10/1979	Uno et al	
	2	4,513,006	4/1985	Marayanoff et al	
	3	6,071,537	6/2000	Shank	
	4	6,191,117	2/2001	Kozachuk	
	5	6,323,236	11/2001	McElroy	
	6	6,506,799	1/2003	Dasseux	
	7	6,548,551	4/2003	Hinz	
	8	20040029941	2/2004	Jennings	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	9	WO 03/092682	11/2003	WIPO		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	10	Ayala, "Weight Loss Associated With the Administration of Zonisamide", AES Proceedings, Epilepsia 41(Suppl. 7) :99 (2000) -No.2.041	
	11	Ayala et al, "Weight Loss Associated With the Administration of Zonisamide", A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, December 1-6, 2000, Los Angeles, California	
	12	Gadde et al, "Zonisamide for Weight Loss in Obese Adults - A Randomized Controlled Trial", JAMA 289(14) :1820-1825 (2003)	
	13	Gadde et al, "Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Women", Obesity Research 9(9) :544-551 (2001)	
	14	Gadde et al, "Randomized Controlled Trial of Zonisamide for Treating Obesity", American Epilepsy Society, http://164.109.45.39/submission/aes/status/...preview.full.asp?presid=2%2E258 , September 11, 2002	
	15	Gadde et al, "Randomized Trial of Weight Loss Efficacy of Zonisamide", No. 304, 26(Suppl. 1), August 2002, International Journal of Obesity and Related Metabolic Disorders, Journal of the International Association for the Study of Obesity, Ninth International Congress on Obesity, Sao Paulo, Brazil, August 24-29, 2002	
	16	Gadde et al, "Zonisamide in Obesity: A 16-Week Randomized Trial", No. NR473, New Research, American Psychiatric Association 2002 Annual Meeting, May 18-23, 2002, Philadelphia, Pennsylvania	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/830,071
	Filing Date	April 23, 2004
	First Named Inventor	Gadde, Kishore M.
	Art Unit	Unassigned
(Multiple sheets used when necessary)	Examiner	Unassigned
SHEET 2 OF 2	Attorney Docket No.	OREX.009C1


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	17	Gadde and Logue, "Bupropion Sustained Release in Obesity: A Randomized Double-Blind, Placebo-Controlled Study", No. NR634, New Research Program & Abstracts, American Psychiatric Association, 1999 Annual Meeting, The Clinician, May 15-20, 1999, Washington, D.C.	
	18	Ginsberg and Sussman, "Effects of Mood Stabilizers on Weight", Primary Psychiatry 7(5):49-58 (2000)	
	19	Grady, "Quest for Weight-Loss Drug Takes an Unusual Turn", The New York Times – Health, www.nytimes.com , March 15, 2003	
	20	Kanios et al, "Compositions and methods for topical administration of pharmaceutically active agents", Database USPT on WEST – USP 5,719,197, February 17, 1998	
	21	Matsuura, "Indication for Anterior Temporal Lobectomy in Patients with Temporal Lobe Epilepsy and Psychopathology", Epilepsia 41(Suppl. 9) :39-42 (2000)	
	22	Morris, III, "The Effect of Zonisamide Administration on Patient Weight", A Scientific Exhibit at the American Epilepsy Society Annual Meeting, December 3, 2000, Los Angeles, California	
	23	Walker et al, "Chronic Toxicity of the Anticonvulsant Zonisamide in Beagle Dogs", Fundamental and Applied Toxicology 11:333-342 (1988)	
	24	Welty et al, "Weight Loss Associated With Use of Zonisamide in European and US Clinical Trials", A Compendium of Posters and Platform Sessions for Zonegran®, Presented at the Annual Meeting 2001 of the American Epilepsy Society, November 30 – December 5, 2001, Philadelphia, Pennsylvania	
	25	Wilner, "Is Weight Loss With Zonisamide Gender-Specific?", Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society, https://secure.neurohub.net/cgi-perl/get.cgi?pub=52318&ext=htm	

S:\DOCS\SKT\SKT-5879.DOC
012105

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.



Docket No.: OREX.009C1

January 26, 2005

Page 1 of 1

Please Direct All Correspondence to Customer Number **20995**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT


Applicant : Gadde, Kishore M.
App. No : 10/830,071
Filed : April 23, 2004
For : METHOD FOR TREATING OBESITY
Examiner : Unassigned
Art Unit : Unassigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 26, 2005

(Date)



Sam K. Tahmassebi, Reg. No. 45,151

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing twenty five (25) references.
 - (X) Enclosing zero (0) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550